| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 33.2 | 22.2 | 25.5 |
| Other income | 0.1 | 0.0 | 0.1 |
| Total income | 33.3 | 22.2 | 25.6 |
| Profit before exceptional items & tax | 1.5 | 0.8 | 1.4 |
| Exceptional items | 0.1 | 0.3 | 0.0 |
| Profit before tax | 1.6 | 1.0 | 1.4 |
| Net profit | 1.3 | 0.8 | 0.9 |
| Operating margin | 4.8% | 4.5% | 5.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +44.40% |
|---|---|
| Net profit, quarter on quarter | +62.50% |
| Revenue, year on year | +30.20% |
BSE results filing, NSE: GODAVARI. Figures extracted from the filing.
Godavari Drugs Ltd: key numbers
- Share price
- ₹125.18
- Market cap
- ₹126.8 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹4.09 Cr
- P/E (TTM)
- 30.5×Sector 50.4×
- Promoter holding
- 40.23%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godavari Drugs Ltd
All →Godavari Drugs Annual General Meeting
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.
Godavari Drugs Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 10.0% YoY
Godavari Drugs Ltd reported revenue from operations of ₹28 Cr (+17.6% YoY) and net profit of ₹1.1 Cr (+10.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · +10.0% YoY